Common adverse effects are constipation and nausea, but rates of discontinuation due to constipation were low for both<unk>  and placebo. Rare adverse effects: fatigue, bronchitis, viral gastroenteritis. Rare serious adverse effects include pancreatitis with a general incidence of 0.3% - higher incidence with 100 mg dose (0.3%) than with 75 mg dose (0.2%). The risk is even greater in those who do not have a gall bladder and the medication is not recommended in this group. In March 2017, the U.S. Food and Drug Administration issued a safety alert for<unk>  concerning an increased risk of serious pancreatitis in patients without a gallbladder. An FDA review found that in such patients, spasm of the sphincter of Oddi may lead to severe pancreatitis. The FDA reported that in some cases symptoms have occurred with just one or two doses at the recommended dosage for patients without a gallbladder (75 mg). Of two deaths associated with<unk>  reported up to February 2017, both occurred in patients without a gallbladder.
Eluxadoline
Acebutolol
Metergoline
Terguride
Clascoterone
Hydrastine
Lumasiran
Tetryzoline